Meeting
2022 ASCO Annual Meeting
Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors.
Authors
Sébastien Perreault
Department of Neurosciences, CHU Hopital Sainte-Justine, Montréal, QC, Canada
Sébastien Perreault , Alexander E. Drilon , Ulrik Niels Lassen , Birgit Geoerger , Karsten Nysom , Ingrid Øra , Igor T. Gavrilovic , Ricarda Norenberg , Marc Mardoche Fellous , Esther A. De La Cuesta , Theodore Willis Laetsch , Francois Doz , Cornelis Martinus van Tilburg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT02637687, NCT02576431
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2010)
DOI
10.1200/JCO.2022.40.16_suppl.2010
Abstract #
2010
Poster Bd #
348
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: Alexander E. Drilon
Poster
2022 ASCO Annual Meeting
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
First Author: Leo Mascarenhas
Poster
2020 ASCO Virtual Scientific Program
Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.
First Author: Alexander E. Drilon
Poster
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: David S. Hong